查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
化療治療的市場至2030年預測：按藥物、藥物途徑、適應症、最終用戶和地區進行的全球分析
市場調查報告書
商品編碼
1383368

化療治療的市場至2030年預測：按藥物、藥物途徑、適應症、最終用戶和地區進行的全球分析

Chemotherapy Treatment Market Forecasts to 2030 - Global Analysis By Drug (Anti-Tumor Antibiotics, Topoisomerase Inhibitors, Alkylating Agents, Mitotic Inhibitors, Antimetabolites and Other Drugs), Route of Drug, Dose, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，2023年全球化療治療市場規模為 88.1 億美元，預計預測期內年複合成長率為 9.5%，到2030年將達到 166.2 億美元。

化療是一種使用藥物消除體內癌細胞或減緩其發展的醫療程序。化療是典型的癌症治療方法，可單獨使用或與手術、放射線治療和免疫療法等其他治療方法合併使用。化療藥物針對快速分裂的細胞，包括癌細胞和一些健康細胞。不幸的是，正常、健康的細胞也會受到治療的影響，這可能導致各種負面影響，包括噁心、脫髮、疲勞和免疫力下降。

根據國際癌症研究機構提供的2021年資料，2020年歐洲地區癌症患者人數為479萬人，預計2040年將增加至607萬人。

癌症盛行率增加

癌症發生率在國際上迅速增加，已超過心血管疾病，成為第二大死因。化療是最常見的癌症治療方法，通常與其他抗癌藥物合併使用。輔助化療是在手術或放療後用於減少癌細胞，這與在手術或放療前進行的新輔助化療不同。因此，在預測期內，全球對腫瘤藥物的需求預計將增加。

藥物的不良反應

化療藥物殺死健康的身體細胞，同時破壞惡性細胞。結果，存在許多個人不想要的副作用。常見的副作用包括皮膚病、脫髮、疲勞、神經病變和骨髓抑制。進一步的阻礙因素包括心臟損傷、紅血球數低、疲勞、脫髮、腹瀉、體重減輕、肝、腎、肺功能下降、骨骼密度下降以及對化療藥物的普遍忽視。這些都是阻礙市場擴張的因素。

創新技術開發

化療對於將癌症患者的壽命延長幾年非常重要。化療的最新進展是將藥物注射到污染區域來治療癌症而不傷害健康細胞。該技術已證明可以去除癌細胞，同時保留健康組織。使用光子雷射器，醫療專業人員可以監測這些奈米顆粒排放到患者體內的情況，並在治療癌細胞時追蹤它們的持續時間和分佈。這就是推動該細分市場擴張的原因。

相關成本高

化療是一種使用藥物殺死體內癌細胞或減緩其發展的醫療程序。它是一種典型的癌症治療方法，可單獨使用或與其他治療方法結合使用。這些藥物針對快速分裂的細胞，包括癌細胞和一些健康細胞。不幸的是，正常、健康的細胞也會受到治療的影響，這可能導致各種負面副作用。由於化療藥物價格高昂，市場擴張預計將緩慢。

COVID-19 的影響：

醫療保健系統受到了 COVID-19大流行的影響，市場也受到了重大影響。這場大流行擾亂了世界各地的藥品和醫療用品的分配。這可能導致化療藥物和其他相關醫療用品的交付延遲或短缺。由於大流行，癌症研究和臨床試驗暫時停止，因為許多研究機構和製藥公司致力於開發 COVID-19 的治療方法和疫苗。這可能推遲了化療等抗癌藥物的開發。

預計在預測期內，口服細分市場將是最大的

預計在預測期內這將是口腔領域最大的一次。用於治療口腔癌的藥物有錠劑、膠囊和液體型態。然而，靜脈注射的成長速度最快。靜脈注射化療藥物比給藥或局部給藥化療藥物起效更快，因為它們更快進入循環。

預計白血病細分市場在預測期內將經歷最高的年複合成長率。

預計白血病領域在預測期內年複合成長率最高。生長緩慢的白血病可能需要監測作為治療的一部分。嚴重白血病的治療可能包括化療、放療和幹細胞移植的組合。女性乳癌發病率的增加，可用治療方法的多樣性以及使用最尖端科技改進乳癌診斷都有助於該領域的擴展。

佔有率最大的地區

預計北美在預測期內將佔據最大的市場佔有率。由於能夠根除癌細胞，化療比其他類型的治療方法越來越受青睞。該市場是由多家化療藥物製造商的存在和不斷成長的醫療保健支出所推動的。該市場也受到醫療設施的便利性以及癌症研究和治療中最尖端科技的使用的推動。

年複合成長率最高的地區：

預計亞太地區在預測期內將維持最高的年複合成長率。這是政府擴大意識提升舉措和降低該地區醫療成本的結果。由於訓練有素且有能力的醫療保健提供者的存在以及對化療藥物不斷成長的需求，擴大了學名藥的獲取範圍，這也導致了該地區市場成長的放緩。政府癌症保險計劃預計將推動市場成長。因此，政府支出和癌症發生率上升將推動市場發展。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與企業的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計/預測/年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 介紹
  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球化療市場：依藥物分類

  • 介紹
  • 抗腫瘤抗生素
  • 拓樸異構酶抑制劑
  • 烷化劑
  • 有絲分裂抑制劑
  • 抗代謝物
  • 其他藥品

第6章 全球化療治療市場：依藥物途徑

  • 介紹
  • 靜脈
  • 口服
  • 皮下
  • 血管內
  • 肌肉注射
  • 腹膜內
  • 局部
  • 腦室內

第7章 全球化療治療市場：依適應症分類

  • 介紹
  • 大腸直腸癌
  • 白血病
  • 攝護腺癌
  • 乳癌
  • 胃癌
  • 肉瘤
  • 肺癌
  • 骨髓瘤
  • 卵巢癌
  • 淋巴瘤
  • 其他適應症

第8章 全球化療治療市場：依最終使用者分類

  • 介紹
  • 醫院和診所
  • 專業中心
  • 研究機構
  • 其他最終用戶

第9章 全球化療治療市場：依地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第10章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • AstraZeneca
  • GlaxoSmithKline
  • Novartis
  • Bayer AG
  • Takeda Pharmaceutical Company Limited
  • Bristol-Myers Squibb
  • Schering-Plough
  • Eli Lilly & Company
  • ImClone Systems Inc.
  • Boehringer Ingelheim
  • E. Hoffmann-La Roche Ltd
  • Merck & Co. Inc.
  • Chemo Espana SL
  • CELGENE CORPORATION
  • Sanofi
  • Teva Pharmaceuticals Industries
  • Pfizer Inc.
  • Amgen Inc
Product Code: SMRC24218

According to Stratistics MRC, the Global Chemotherapy Market is accounted for $8.81 billion in 2023 and is expected to reach $16.62 billion by 2030 growing at a CAGR of 9.5% during the forecast period. Chemotherapy is a medical procedure that uses medications to either eliminate or slow the development of cancer cells in the body. It is a typical method of treating cancer and may be used alone or in combination with other treatments including surgery, radiation therapy, or immunotherapy. Chemotherapy medications target cells that divide quickly, including both cancer cells and some healthy cells. Unfortunately, as normal, healthy cells are also impacted by the treatment, this can result in a number of negative side effects, including nausea, hair loss, exhaustion, and a weaker immune system.

According to data from 2021 provided by the International Agency for the Research on Cancer, there were 4.79 million cancer cases in the European region in 2020, and that number is projected to rise to 6.07 million by 2040.

Market Dynamics:

Driver:

Increasing prevalence of cancer

Cancer incidence has surged internationally, surpassing cardiovascular disease as the second greatest cause of death. Chemotherapy, the most common type of cancer treatment, is commonly coupled with other cancer medicines. Contrary to neo-adjuvant chemotherapy, which is administered prior to surgery and radiation therapy, adjuvant chemotherapy is used to reduce the tumor cell after surgery or radiation therapy. As a result, it is predicted that throughout the projected period, there will be a global increase in demand for oncology cancer medications.

Restraint:

Negative effects of drugs

Chemotherapy drugs kill healthy body cells while destroying malignant cells. This includes a number of unfavourable side effects for the individuals. Some common adverse effects include skin problems, hair loss, tiredness, neuropathies, and bone marrow suppression. A further disincentive will be the adverse effects of chemotherapy drugs, such as heart problems, low red blood cell counts, tiredness, hair loss, diarrhea, weight loss, impaired liver, kidney, and lung function, decreased bone density, and general ignorance. These are the elements limiting the market's expansion.

Opportunity:

Development of innovative technology

Chemotherapy has been essential in extending cancer patients' lives for a few more years than they otherwise would have. The most recent development in chemotherapy involves injecting drugs that treat cancer without hurting healthy cells into polluted regions. It has been demonstrated that using this technique keeps healthy tissue intact while removing cancerous cells. Using photon lasers, medical professionals may monitor the discharge of these nanoparticles into a patient's body and follow their duration and distribution while treating cancerous cells. This is the element propelling the segment's expansion.

Threat:

High associated costs

Chemotherapy is a medical procedure that uses medications to either eliminate or slow the development of cancer cells in the body. It is a typical method of treating cancer and may be used alone or in combination with other treatments. These medications target cells that divide quickly, including both cancer cells and some healthy cells. Unfortunately, as normal, healthy cells are also impacted by the treatment, this can result in a number of negative side effects. The high price of the chemotherapy drug will slow the market's expansion.

COVID-19 Impact:

The healthcare systems have been impacted by the COVID-19 pandemic, and the market has also been significantly impacted. The epidemic hampered the flow of drugs and medical supplies around the globe. This might have resulted in delays or shortages in the delivery of chemotherapy medications and other relevant medical supplies. Cancer research and clinical trials were briefly put on hold as a result of the pandemic as many institutes and pharmaceutical corporations concentrated on creating cures and vaccinations for COVID-19. This could have slowed down developments in cancer medicines like chemotherapy.

The oral segment is expected to be the largest during the forecast period

The oral segment is expected to be the largest during the forecast period. A medicine used to treat oral cancer comes in the form of a tablet, capsule, or liquid. The fastest growth rate was, however, seen with intravenous administration. Chemotherapy medications work faster because they are taken into the circulation promptly when given intravenously than when given orally or topically.

The leukemia segment is expected to have the highest CAGR during the forecast period

The leukemia segment is expected to have the highest CAGR during the forecast period. Slow-growing leukemias may require monitoring as part of their therapy. To treat severe leukemias, a combination of chemotherapy, radiation treatment, and stem cell transplantation may be employed. The rising incidence of breast cancer in women, the diversity of treatments available, and enhanced techniques for breast cancer diagnosis employing cutting-edge technology all contribute to the sector's expansion.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. Chemotherapy is increasingly being preferred over other types of treatment because of its capacity to eradicate cancer cells. The market is primarily driven by the presence of multiple chemotherapy medication producers and an increase in healthcare spending. The market is also being driven by the accessibility of healthcare facilities and the use of cutting-edge technology in the investigation and treatment of cancer.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. It is a result of expanded government awareness initiatives and g rowing healthcare costs in this area. Due to the availability of trained and competent healthcare providers and the rising need for chemotherapy drugs, the expanding accessibility of generic pharmaceuticals will also help to slow the market's rate of progress in this area. Government cancer insurance programs are anticipated to drive market growth. Government expenditure and a rise in the incidence of cancer will thus drive the market.

Key players in the market

Some of the key players in Chemotherapy market include: AstraZeneca, GlaxoSmithKline, Novartis, Bayer AG, Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb, Schering-Plough, Eli Lilly & Company, ImClone Systems Inc., Boehringer Ingelheim, E. Hoffmann-La Roche Ltd, Merck & Co. Inc., Chemo Espana SL, CELGENE CORPORATION, Sanofi, Teva Pharmaceuticals Industries, Pfizer Inc. and Amgen Inc.

Key Developments:

In October 2023, Novartis present new data from 29 Novartis and investigator-led abstracts at the European Society for Medical Oncology (ESMO) Congress 2023, highlighting latest developments from across its oncology portfolio and addressing unmet needs of patients diagnosed with some of the most prevalent cancers, including prostate and breast.

In February 2023, Pfizer announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI in men with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations.

Drugs Covered:

  • Anti-Tumor Antibiotics
  • Topoisomerase Inhibitors
  • Alkylating Agents
  • Mitotic Inhibitors
  • Antimetabolites
  • Other Drugs

Route of Drugs Covered:

  • Intravenous
  • Oral
  • Subcutaneous
  • Intravascular
  • Intra-Muscular
  • Intraperitoneal
  • Topical
  • Intraventricular

Indications Covered:

  • Colorectal Cancer
  • Leukemia
  • Prostate Cancer
  • Breast Cancer
  • Stomach Cancer
  • Sarcoma
  • Lung Cancer
  • Myeloma
  • Ovarian Cancer
  • Lymphoma
  • Other Indications

End Users Covered:

  • Hospitals & Clinics
  • Specialty Centers
  • Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Chemotherapy Market, By Drug

  • 5.1 Introduction
  • 5.2 Anti-Tumor Antibiotics
  • 5.3 Topoisomerase Inhibitors
  • 5.4 Alkylating Agents
  • 5.5 Mitotic Inhibitors
  • 5.6 Antimetabolites
  • 5.7 Other Drugs

6 Global Chemotherapy Market, By Route of Drug

  • 6.1 Introduction
  • 6.2 Intravenous
  • 6.3 Oral
  • 6.4 Subcutaneous
  • 6.5 Intravascular
  • 6.6 Intra-Muscular
  • 6.7 Intraperitoneal
  • 6.8 Topical
  • 6.9 Intraventricular

7 Global Chemotherapy Market, By Indication

  • 7.1 Introduction
  • 7.2 Colorectal Cancer
  • 7.3 Leukemia
  • 7.4 Prostate Cancer
  • 7.5 Breast Cancer
  • 7.6 Stomach Cancer
  • 7.7 Sarcoma
  • 7.8 Lung Cancer
  • 7.9 Myeloma
  • 7.10 Ovarian Cancer
  • 7.11 Lymphoma
  • 7.12 Other Indications

8 Global Chemotherapy Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Specialty Centers
  • 8.4 Research Institutes
  • 8.5 Other End Users

9 Global Chemotherapy Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 AstraZeneca
  • 11.2 GlaxoSmithKline
  • 11.3 Novartis
  • 11.4 Bayer AG
  • 11.5 Takeda Pharmaceutical Company Limited
  • 11.6 Bristol-Myers Squibb
  • 11.7 Schering-Plough
  • 11.8 Eli Lilly & Company
  • 11.9 ImClone Systems Inc.
  • 11.10 Boehringer Ingelheim
  • 11.11 E. Hoffmann-La Roche Ltd
  • 11.12 Merck & Co. Inc.
  • 11.13 Chemo Espana SL
  • 11.14 CELGENE CORPORATION
  • 11.15 Sanofi
  • 11.16 Teva Pharmaceuticals Industries
  • 11.17 Pfizer Inc.
  • 11.18 Amgen Inc

List of Tables

  • Table 1 Global Chemotherapy Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Chemotherapy Market Outlook, By Drug (2021-2030) ($MN)
  • Table 3 Global Chemotherapy Market Outlook, By Anti-Tumor Antibiotics (2021-2030) ($MN)
  • Table 4 Global Chemotherapy Market Outlook, By Topoisomerase Inhibitors (2021-2030) ($MN)
  • Table 5 Global Chemotherapy Market Outlook, By Alkylating Agents (2021-2030) ($MN)
  • Table 6 Global Chemotherapy Market Outlook, By Mitotic Inhibitors (2021-2030) ($MN)
  • Table 7 Global Chemotherapy Market Outlook, By Antimetabolites (2021-2030) ($MN)
  • Table 8 Global Chemotherapy Market Outlook, By Other Drugs (2021-2030) ($MN)
  • Table 9 Global Chemotherapy Market Outlook, By Route of Drug (2021-2030) ($MN)
  • Table 10 Global Chemotherapy Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 11 Global Chemotherapy Market Outlook, By Oral (2021-2030) ($MN)
  • Table 12 Global Chemotherapy Market Outlook, By Subcutaneous (2021-2030) ($MN)
  • Table 13 Global Chemotherapy Market Outlook, By Intravascular (2021-2030) ($MN)
  • Table 14 Global Chemotherapy Market Outlook, By Intra-Muscular (2021-2030) ($MN)
  • Table 15 Global Chemotherapy Market Outlook, By Intraperitoneal (2021-2030) ($MN)
  • Table 16 Global Chemotherapy Market Outlook, By Topical (2021-2030) ($MN)
  • Table 17 Global Chemotherapy Market Outlook, By Intraventricular (2021-2030) ($MN)
  • Table 18 Global Chemotherapy Market Outlook, By Indication (2021-2030) ($MN)
  • Table 19 Global Chemotherapy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 20 Global Chemotherapy Market Outlook, By Leukemia (2021-2030) ($MN)
  • Table 21 Global Chemotherapy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
  • Table 22 Global Chemotherapy Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 23 Global Chemotherapy Market Outlook, By Stomach Cancer (2021-2030) ($MN)
  • Table 24 Global Chemotherapy Market Outlook, By Sarcoma (2021-2030) ($MN)
  • Table 25 Global Chemotherapy Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 26 Global Chemotherapy Market Outlook, By Myeloma (2021-2030) ($MN)
  • Table 27 Global Chemotherapy Market Outlook, By Ovarian Cancer (2021-2030) ($MN)
  • Table 28 Global Chemotherapy Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 29 Global Chemotherapy Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 30 Global Chemotherapy Market Outlook, By End User (2021-2030) ($MN)
  • Table 31 Global Chemotherapy Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 32 Global Chemotherapy Market Outlook, By Specialty Centers (2021-2030) ($MN)
  • Table 33 Global Chemotherapy Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 34 Global Chemotherapy Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.